Cardiol Therapeutics Files 6-K
Ticker: CRDL · Form: 6-K · Filed: Apr 16, 2025 · CIK: 1702123
Sentiment: neutral
Topics: filing, news-release
TL;DR
Cardiol Therapeutics filed a 6-K on 4/16/25, likely with a news release attached.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on April 16, 2025, to report a news release dated April 16, 2025. The filing does not contain specific financial figures or operational updates beyond the submission of this news release.
Why It Matters
This filing indicates that Cardiol Therapeutics Inc. is providing an update to the SEC, likely related to recent corporate events or news, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is a routine submission of a news release and does not contain new financial data or significant operational changes that would immediately alter risk.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- April 16, 2025 (date) — Filing and News Release Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a news release dated April 16, 2025, submitted by Cardiol Therapeutics Inc.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 16, 2025.
What is the principal executive office address for Cardiol Therapeutics Inc.?
The principal executive office address is 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics Inc. indicates it files annual reports under Form 40-F.
What exhibit is submitted with this Form 6-K?
Exhibit 99.1, a News Release dated April 16, 2025, is submitted with this Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 16, 2025 regarding Cardiol Therapeutics Inc. (CRDL).